Abstract
We propose a two-stage strategy, called the Limb-Leaf method, to explore the dose-response curve using dose promotion and addition in the context of adaptive seamless Phase II/III trials. Strong control of the overall type 1 familywise error rate of the proposed method is enforced by the closed testing principle. The design constants are determined to minimize the risk-adjusted expected total sample size while maintaining a target power. In the case of a nonmonotonic dose response curve where more doses are required to adequately explore the curve, substantial savings in sample size are achieved compared with a traditional strategy which offers only selection and promotion from among initial first stage doses.
Original language | English |
---|---|
Pages (from-to) | 210-218 |
Number of pages | 9 |
Journal | Contemporary Clinical Trials |
Volume | 64 |
DOIs | |
State | Published - Jan 2018 |
Keywords
- Adaptive design
- Closed testing principle
- Dose addition
- Dose-response curve
- Nonmonotonicity